Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 7
2005 4
2006 3
2007 9
2008 7
2009 2
2010 3
2011 4
2012 7
2013 9
2014 6
2015 11
2016 7
2017 11
2018 11
2019 11
2020 17
2021 16
2022 11
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: cope ap. Ann Rheum Dis. 2023 Aug;82(8):1059-1067. doi: 10.1136/ard-2023-224049. Epub 2023 May 29. Ann Rheum Dis. 2023. PMID: 37247942 Free PMC article.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: cope ap. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.
Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C. Liszewski MK, et al. Among authors: cope a. Immunity. 2013 Dec 12;39(6):1143-57. doi: 10.1016/j.immuni.2013.10.018. Epub 2013 Dec 5. Immunity. 2013. PMID: 24315997 Free PMC article.
Emerging therapies for pre-RA.
Cope AP. Cope AP. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):99-111. doi: 10.1016/j.berh.2017.08.005. Epub 2017 Sep 11. Best Pract Res Clin Rheumatol. 2017. PMID: 29221603 Review.
Baricitinib set to join the Covid-19 therapeutic arsenal?
Gudu T, Stober C, Cope AP, Cheriyan J, Galloway J, Wilkinson IB, Kostapanos M, Jayne D, Hall F. Gudu T, et al. Among authors: cope ap. Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061. Rheumatology (Oxford). 2021. PMID: 33502499 Free PMC article. No abstract available.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Among authors: cope ap. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG; RA-MAP Consortium; Isaacs JD. Cooles FAH, et al. Among authors: cope ap. Ann Rheum Dis. 2022 Aug 11;81(9):1214-1223. doi: 10.1136/annrheumdis-2022-222370. Ann Rheum Dis. 2022. PMID: 35680389 Free PMC article.
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?
van Steenbergen HW, Cope AP, van der Helm-van Mil AHM. van Steenbergen HW, et al. Among authors: cope ap. Nat Rev Rheumatol. 2023 Dec;19(12):767-777. doi: 10.1038/s41584-023-01035-y. Epub 2023 Oct 9. Nat Rev Rheumatol. 2023. PMID: 37814057 Review.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.
163 results